Deoxyspergualin is a new radioprotector in mice.
A novel immunosuppressant, deoxyspergualin, given at doses of 2.5 to 20 mg/kg/day on days -3, -2 and -1 before X irradiation protected BALB/c mice from the lethal effects of radiation in a dose-dependent manner. The dose of radiation that killed 50% of the mice within 30 days was 5.63 Gy for mice receiving radiation alone, but was 7.13 Gy in the mice given deoxyspergualin at 20 mg/kg. Prior administration of deoxyspergualin ameliorated leukopenia and thrombocytopenia induced by sublethal irradiation, and significantly increased the number of femoral spleen colony-forming units (CFU-S) that survived irradiation. Deoxyspergualin also reduced the proportion of CFU-S in S phase, as determined by in vitro sensitivity to hydroxyurea. These findings suggest that deoxyspergualin may be effective in the prevention of hematopoietic injury caused by radiotherapy.
Nemoto
K
K
Research Center of Charged Particle Therapy, National Institute of Radiological Science, Chiba-shi, Japan.
Horiuchi
K
K
Miyamoto
T
T
D000818:Animals; D001792:Blood Platelets / Q000187:drug effects / Q000528:radiation effects; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D005260:Female; D006146:Guanidines / Q000494:pharmacology*; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects; D007962:Leukocytes / Q000187:drug effects / Q000528:radiation effects; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D011837:Radiation-Protective Agents / Q000494:pharmacology*
D006146:Guanidines; D011837:Radiation-Protective Agents; C037258:gusperimus